Targeting EGFR/ERBB2 with Neratinib in Hormone Receptor (HR)-positive/HER2-negative HER2-enriched advanced/metastatic breast cancer
Aleix Prat, MD, PhD (Hospital Clínic de Barcelona)
Eva Ciruelos, MD, PhD (Hospital 12 de octubre, Madrid)
Cristina Saura, MD, PhD (Vall d’Hebron Institut d’Oncologia, Barcelona)